161 related articles for article (PubMed ID: 25024072)
1. Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer.
Shuch B; Agochukwu N; Ricketts CJ; Vocke CD; Gautam R; Merino M; Linehan WM; Srinivasan R
J Clin Oncol; 2016 Mar; 34(9):e76-9. PubMed ID: 25024072
[No Abstract] [Full Text] [Related]
2. Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.
Stewart GD; O'Mahony FC; Laird A; Rashid S; Martin SA; Eory L; Lubbock AL; Nanda J; O'Donnell M; Mackay A; Mullen P; McNeill SA; Riddick AC; Aitchison M; Berney D; Bex A; Overton IM; Harrison DJ; Powles T
Eur Urol; 2014 Nov; 66(5):956-63. PubMed ID: 24821582
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.
Yuasa T; Takahashi S; Hatake K; Yonese J; Fukui I
Cancer Sci; 2011 Nov; 102(11):1949-57. PubMed ID: 21812860
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Hutson TE; Escudier B; Esteban E; Bjarnason GA; Lim HY; Pittman KB; Senico P; Niethammer A; Lu DR; Hariharan S; Motzer RJ
J Clin Oncol; 2014 Mar; 32(8):760-7. PubMed ID: 24297950
[TBL] [Abstract][Full Text] [Related]
6. Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.
De Vincenzo F; Zucali PA; Ceresoli GL; Colombo P; Simonelli M; Lorenzi E; Perrino M; Gianoncelli L; De Sanctis R; Graziotti P; Santoro A
J Clin Oncol; 2011 Jun; 29(18):e529-31. PubMed ID: 21483010
[No Abstract] [Full Text] [Related]
7. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
[TBL] [Abstract][Full Text] [Related]
8. New challenges in kidney cancer therapy: sunitinib.
Izzedine H; Billemont B; Thibault F; Rixe O
Ann Oncol; 2007 Jul; 18 Suppl 9():ix83-6. PubMed ID: 17631600
[No Abstract] [Full Text] [Related]
9. Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.
Beuselinck B; Jean-Baptiste J; Schöffski P; Couchy G; Meiller C; Rolland F; Allory Y; Joniau S; Verkarre V; Elaidi R; Lerut E; Roskams T; Patard JJ; Oudard S; Méjean A; Lambrechts D; Zucman-Rossi J
BJU Int; 2016 Dec; 118(6):890-901. PubMed ID: 27417418
[TBL] [Abstract][Full Text] [Related]
10. Therapy for metastatic RCC--questions remain.
Breau RH; Leibovich BC
Nat Rev Urol; 2009 Nov; 6(11):580-1. PubMed ID: 19890336
[No Abstract] [Full Text] [Related]
11. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for patients with renal-cell carcinoma.
Rini BI
Lancet Oncol; 2011 Nov; 12(12):1085-7. PubMed ID: 22015058
[No Abstract] [Full Text] [Related]
13. Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
J Urol; 2016 Nov; 196(5):1363-1370. PubMed ID: 27288695
[TBL] [Abstract][Full Text] [Related]
14. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; van Poppel H; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; Joly F; Lebret T; Gravis G; Deplanque G; Descazeaud A; Leclercq NR; Molinié V; Patard JJ; Teghom C; Elaidi R; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Jan; 53(1):103-12. PubMed ID: 23421954
[TBL] [Abstract][Full Text] [Related]
15. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
Stein MN; Flaherty KT
Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
[No Abstract] [Full Text] [Related]
16. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma.
Narayanan S; Callis-Duffin K; Batten J; Agarwal N
Am J Med Sci; 2010 Jun; 339(6):580-1. PubMed ID: 20421784
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib therapy in renal cell carcinoma.
O'Brien MF; Russo P; Motzer RJ
BJU Int; 2008 Jun; 101(11):1339-42. PubMed ID: 18284408
[No Abstract] [Full Text] [Related]
18. Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.
Gyawali B; Ando Y
Ann Oncol; 2017 Apr; 28(4):898-899. PubMed ID: 27993814
[No Abstract] [Full Text] [Related]
19. Re: Grant D. Stewart, Fiach C. O'Mahony, Alexander Laird, et al. carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.007.
Kroeger N; Pantuck AJ
Eur Urol; 2014 Oct; 66(4):e69-70. PubMed ID: 24973996
[No Abstract] [Full Text] [Related]
20. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Shaheen PE; Rini BI; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]